Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML

Photo by National Institute of Allergy and Infectious Diseases / Unsplash

Frontiers in Medicine Published June 4, 2026 Medically reviewed June 4, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider these novel strategies as investigational; clinical data are needed to confirm separation of GVHD from GVL.

This narrative review examines emerging strategies to dissociate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) effects in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The authors discuss a range of novel approaches, including selective modulation of T-cell trafficking, enhancement of tissue tolerance, cellular therapies, selective immune modulation, restoration of leukemia immunogenicity, targeted elimination of leukemia stem cells, reshaping the tumor immune microenvironment, and modulation of T-cell exhaustion. The primary goal is to preserve the beneficial GVL effect while minimizing GVHD. The review is qualitative in nature, as no pooled effect sizes or primary outcome data are reported. The authors do not specify limitations or provide a certainty assessment, and no safety data or practice recommendations are included. Given the narrative format and lack of quantitative synthesis, the findings should be interpreted as a conceptual overview rather than definitive clinical guidance. Further research, including clinical trials, is needed to validate these strategies.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for various hematologic malignancies. Separation of graft-versus-leukemia (GVL) effects from graft-versus-host disease (GVHD) remains one of the central challenges in allo-HCT. However, relapse after allo-HCT remains associated with poor prognosis, and effective strategies that preserve graft-versus-leukemia (GVL) effects while preventing graft-versus-host disease (GVHD) are still lacking. Recent advances have revealed that post-transplant relapse is driven by diverse mechanisms, including leukemia-intrinsic immune escape, donor T-cell exhaustion, and persistence of leukemia stem cells. Emerging therapeutic strategies, such as selective modulation of T-cell trafficking and enhancement of tissue tolerance, are promising approaches to ameliorate GVHD without attenuating GVL effects. Additional approaches including cellular therapies, selective immune modulation, and restoration of leukemia immunogenicity are also being actively explored. Furthermore, restoration of leukemia immunogenicity and targeted elimination of leukemia stem cells are expected to provide new opportunities to prevent relapse without aggravating GVHD. In addition, approaches that reshape the tumor immune microenvironment or modulate T-cell exhaustion may further strengthen GVL activity while limiting harmful alloreactivity. These developments suggest that the long-considered difficult goal of separating GVHD from GVL effects may become achievable in the near future. In this review, we provide an overview of novel therapeutic targets aimed at achieving the separation of GVHD and GVL, with a particular focus on findings related to acute myeloid leukemia.